ES2629509T3 - Integración específica de sitio - Google Patents
Integración específica de sitio Download PDFInfo
- Publication number
- ES2629509T3 ES2629509T3 ES13729962.4T ES13729962T ES2629509T3 ES 2629509 T3 ES2629509 T3 ES 2629509T3 ES 13729962 T ES13729962 T ES 13729962T ES 2629509 T3 ES2629509 T3 ES 2629509T3
- Authority
- ES
- Spain
- Prior art keywords
- gene
- host cell
- cell
- interest
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000010354 integration Effects 0.000 title claims abstract description 51
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 235
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 83
- 239000002773 nucleotide Substances 0.000 claims abstract description 82
- 238000005215 recombination Methods 0.000 claims abstract description 81
- 230000006798 recombination Effects 0.000 claims abstract description 79
- 210000004027 cell Anatomy 0.000 claims description 339
- 239000013598 vector Substances 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 52
- 238000004519 manufacturing process Methods 0.000 claims description 40
- 239000003550 marker Substances 0.000 claims description 40
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 22
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 17
- 108020004440 Thymidine kinase Proteins 0.000 claims description 17
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 15
- 229950010131 puromycin Drugs 0.000 claims description 11
- 101710163270 Nuclease Proteins 0.000 claims description 6
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 235000021410 healthy eating index Nutrition 0.000 claims description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 21
- 230000008569 process Effects 0.000 description 18
- 238000001890 transfection Methods 0.000 description 17
- 108010046276 FLP recombinase Proteins 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 12
- 229930182817 methionine Natural products 0.000 description 12
- 108020005065 3' Flanking Region Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229960002963 ganciclovir Drugs 0.000 description 9
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 108700024394 Exon Proteins 0.000 description 8
- 108020005029 5' Flanking Region Proteins 0.000 description 7
- 241000699802 Cricetulus griseus Species 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 108090000204 Dipeptidase 1 Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000003559 RNA-seq method Methods 0.000 description 5
- 108010091086 Recombinases Proteins 0.000 description 5
- 102000018120 Recombinases Human genes 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 102000005421 acetyltransferase Human genes 0.000 description 5
- 108020002494 acetyltransferase Proteins 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 102000006635 beta-lactamase Human genes 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000012268 genome sequencing Methods 0.000 description 4
- 102000005396 glutamine synthetase Human genes 0.000 description 4
- 108020002326 glutamine synthetase Proteins 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101100173542 Caenorhabditis elegans fer-1 gene Proteins 0.000 description 3
- 108010051219 Cre recombinase Proteins 0.000 description 3
- 108010042653 IgA receptor Proteins 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 102000002110 C2 domains Human genes 0.000 description 2
- 108050009459 C2 domains Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150074355 GS gene Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011965 cell line development Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- UJHBVMHOBZBWMX-UHFFFAOYSA-N ferrostatin-1 Chemical compound NC1=CC(C(=O)OCC)=CC=C1NC1CCCCC1 UJHBVMHOBZBWMX-UHFFFAOYSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 108010002685 hygromycin-B kinase Proteins 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940065638 intron a Drugs 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101150027568 LC gene Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- 101710113649 Thyroid peroxidase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- -1 pH 7.7 Chemical compound 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663147P | 2012-06-22 | 2012-06-22 | |
| US201261663147P | 2012-06-22 | ||
| EP12185330.3A EP2711428A1 (en) | 2012-09-21 | 2012-09-21 | Site-specific integration |
| EP12185330 | 2012-09-21 | ||
| PCT/EP2013/062859 WO2013190032A1 (en) | 2012-06-22 | 2013-06-20 | Site-specific integration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2629509T3 true ES2629509T3 (es) | 2017-08-10 |
Family
ID=46888327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13729962.4T Active ES2629509T3 (es) | 2012-06-22 | 2013-06-20 | Integración específica de sitio |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10280436B2 (enExample) |
| EP (2) | EP2711428A1 (enExample) |
| JP (1) | JP6053923B2 (enExample) |
| KR (1) | KR101761709B1 (enExample) |
| CN (1) | CN104379753B (enExample) |
| AU (1) | AU2013279333C1 (enExample) |
| BR (1) | BR112014032299B1 (enExample) |
| CA (1) | CA2876280C (enExample) |
| DK (1) | DK2864489T3 (enExample) |
| EA (1) | EA034039B1 (enExample) |
| ES (1) | ES2629509T3 (enExample) |
| IL (1) | IL236347A0 (enExample) |
| IN (1) | IN2014MN02518A (enExample) |
| MX (1) | MX351727B (enExample) |
| PL (1) | PL2864489T3 (enExample) |
| SG (1) | SG11201408576QA (enExample) |
| TW (1) | TWI523946B (enExample) |
| WO (1) | WO2013190032A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| CN113981027A (zh) * | 2015-04-27 | 2022-01-28 | 动量制药公司 | 制备治疗性蛋白质的方法 |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| EP3408397B1 (en) | 2016-01-27 | 2020-07-15 | Just-Evotec Biologics, Inc. | Hybrid promoter and uses thereof |
| EP3445780A1 (en) * | 2016-04-20 | 2019-02-27 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| TWI827531B (zh) * | 2016-04-20 | 2024-01-01 | 美商再生元醫藥公司 | 基於使用增強表現基因座之製備抗體的組成物及方法 |
| CA3053712A1 (en) * | 2017-02-17 | 2018-08-23 | Lonza Ltd. | Multi-site specific integration cells for difficult to express proteins |
| CA3053304A1 (en) * | 2017-02-17 | 2018-08-23 | Lonza Ltd. | Mammalian cells for producing adeno-associated viruses |
| GB201703418D0 (en) * | 2017-03-03 | 2017-04-19 | Ge Healthcare Bio Sciences Ab | Method for cell line development |
| CA3056182A1 (en) | 2017-03-16 | 2018-09-20 | Pfizer Inc. | Tyrosine prototrophy |
| CN107557390A (zh) * | 2017-09-18 | 2018-01-09 | 江南大学 | 一种筛选cho细胞系高表达位点的方法 |
| IL275462B1 (en) * | 2017-12-22 | 2025-09-01 | Genentech Inc | Targeted integration of nucleic acids |
| JP7549582B2 (ja) * | 2018-10-01 | 2024-09-11 | ロンザ リミテッド | 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法 |
| AU2019403279A1 (en) * | 2018-12-21 | 2021-07-01 | Genentech, Inc. | Targeted integration of nucleic acids |
| EP3950938A4 (en) * | 2019-04-02 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR INTRODUCING A FOREIGN TARGET-SPECIFIC GENE |
| KR20220097910A (ko) | 2019-11-14 | 2022-07-08 | 론자 리미티드 | 세포 선택 방법 |
| KR102335242B1 (ko) | 2020-05-22 | 2021-12-02 | 인천대학교 산학협력단 | Fer1L4 유전자에 부위-특이적 통합된 RMCE 랜딩 패드를 포함하는 CHO 세포 |
| US20230287455A1 (en) | 2020-07-30 | 2023-09-14 | Pfizer Inc. | Cells Having Gene Duplications and Uses Thereof |
| JP2024528139A (ja) | 2021-08-02 | 2024-07-26 | ファイザー・インク | 改良された発現ベクターおよびその使用 |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| WO2023148598A1 (en) | 2022-02-02 | 2023-08-10 | Pfizer Inc. | Cysteine prototrophy |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE69840439D1 (de) | 1997-04-24 | 2009-02-26 | Univ Washington | Zielgerichtete genveraenderung mit parvoviralen vektoren |
| BRPI0513706A (pt) * | 2004-07-20 | 2008-05-13 | Symphogen As | anticorpo policlonal recombinante anti-rhesus d e métodos de produção |
| JP4665115B2 (ja) * | 2004-08-06 | 2011-04-06 | 独立行政法人理化学研究所 | 骨・関節疾患感受性遺伝子およびその用途 |
| WO2007014275A2 (en) | 2005-07-26 | 2007-02-01 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
-
2012
- 2012-09-21 EP EP12185330.3A patent/EP2711428A1/en not_active Withdrawn
-
2013
- 2013-06-20 SG SG11201408576QA patent/SG11201408576QA/en unknown
- 2013-06-20 BR BR112014032299-6A patent/BR112014032299B1/pt not_active IP Right Cessation
- 2013-06-20 MX MX2014015612A patent/MX351727B/es active IP Right Grant
- 2013-06-20 EP EP13729962.4A patent/EP2864489B1/en active Active
- 2013-06-20 CN CN201380032837.8A patent/CN104379753B/zh active Active
- 2013-06-20 AU AU2013279333A patent/AU2013279333C1/en not_active Ceased
- 2013-06-20 JP JP2015517758A patent/JP6053923B2/ja active Active
- 2013-06-20 EA EA201590068A patent/EA034039B1/ru not_active IP Right Cessation
- 2013-06-20 CA CA2876280A patent/CA2876280C/en active Active
- 2013-06-20 IN IN2518MUN2014 patent/IN2014MN02518A/en unknown
- 2013-06-20 PL PL13729962T patent/PL2864489T3/pl unknown
- 2013-06-20 DK DK13729962.4T patent/DK2864489T3/en active
- 2013-06-20 US US14/409,283 patent/US10280436B2/en active Active
- 2013-06-20 WO PCT/EP2013/062859 patent/WO2013190032A1/en not_active Ceased
- 2013-06-20 KR KR1020157000511A patent/KR101761709B1/ko active Active
- 2013-06-20 ES ES13729962.4T patent/ES2629509T3/es active Active
- 2013-06-21 TW TW102122188A patent/TWI523946B/zh not_active IP Right Cessation
-
2014
- 2014-12-18 IL IL236347A patent/IL236347A0/en active IP Right Grant
-
2018
- 2018-10-31 US US16/176,525 patent/US11326185B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2629509T3 (es) | Integración específica de sitio | |
| AU2017268458B2 (en) | Methods for breaking immunological tolerance using multiple guide RNAS | |
| MXPA03010626A (es) | Plataformas a base de cromosomas. | |
| EP2898077B1 (en) | Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences | |
| US20220089775A1 (en) | Multiply auxotrophic cell line for the production of recombinant proteins and methods thereof | |
| CN103834686B (zh) | 高效克隆筛选表达载体、其制备方法及用途 | |
| WO2019096054A1 (zh) | 一种筛选谷氨酰胺合成酶缺陷型hek293细胞株的方法 | |
| JP4998814B2 (ja) | Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法 | |
| JP2010522549A (ja) | 目的のポリヌクレオチドの発現を増強するためのポリヌクレオチド | |
| JP4568378B2 (ja) | 遺伝子発現安定化エレメント | |
| CN120035660A (zh) | 基因转移效率增强的转座酶突变体 | |
| CN111040028B (zh) | 能促进较大基因表达的Bcl2突变体及应用 | |
| CN105695509B (zh) | 一种获得高纯度心肌细胞的方法 | |
| RU2842438C1 (ru) | Способы преодоления иммунологической толерантности с использованием множества направляющих рнк | |
| HK1202580B (zh) | 位点特异性整合 | |
| CN113564205B (zh) | 一种平衡染色体动物模型的构建方法 | |
| US20230313173A1 (en) | Systems and methods for identifying cells that have undergone genome editing | |
| RU2829155C2 (ru) | Способы преодоления иммунологической толерантности с использованием множества направляющих рнк | |
| KR101634244B1 (ko) | Talen을 이용하여 grk5 넉아웃 마우스를 제조하는 방법 | |
| WO2006080248A1 (ja) | 線状哺乳類人工染色体及びその構築方法 |